Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Haploidentical SCT with Post-Transplant Cyclophosphamide
NCT02248597Phase 2Completed
- Sponsor
- Wake Forest University Health Sciences
- Start
- Feb 2015
- Primary completion
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of cyclophosphamide in hematological malignancy, graft-versus-host disease (GVHD), sponsored by Wake Forest University Health Sciences. Started Feb 2015; status: completed.
02
Drugs
cyclophosphamide
03
Conditions
hematological malignancygraft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT02248597.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02248597.